On May 26, 10 major industrialization projects of CMC were completed and put into production, marking further acceleration of CMC's industrialization. These projects include biological products, innovative chemical preparations, diagnostic reagents and drug packaging materials, covering almost all aspects of the bio-pharmaceutical field.
Advanced technology and broad market prospects are the common characteristics of these products. The suspended live vaccine for highly pathogenic porcine reproductive and respiratory syndrome, independently developed by Sinovet (Jiangsu) Biopharmaceutical Co., Ltd. marks the first attempt of applying the suspension process to a live vaccine in China and was officially launched on the market in this May. The company's combined live vaccine for highly pathogenic porcine reproductive and respiratory syndrome and swine fever is an international original technology and its inactivated bovine viral diarrhea vaccine (BVDV) is the first of its kind in China and will be launched on the market in July. The automatic tube chemiluminescence immunoassay system, independently developed by Taizhou Zecheng Biotechnology Co., Ltd. holds a leading position in the international immunoassay field and has filled the gap in the domestic field.
The Category 1.1 new drugs are drugs with the most core competencies and cutting-edge R&D value that have not yet been marketed at home and abroad and are subject to the most stringent national regulatory requirements. 3 out of the 10 projects are Category 1.1 new drugs. The uroacitides injection (Xidike), a Category 1.1 new drug developed by NT Biopharmaceutical Jiangsu Co., Ltd., is an exclusive product worldwide and mainly used for the treatment of non-small cell lung cancer and breast cancer, etc. It is currently under Phase II clinical trial for the treatment of myelodysplastic syndromes (MDS). The company is expected to generate an invoiced sales of RMB 100 million and taxes of RMB 20 million this year and create an annual sales of RMB 500 million and taxes of RMB 100 million in 3 years.
Last year, only 2 new vaccines applied for production across China. One is the influenza split vaccine (Sijia), a Category 1.1 new drug developed by Jiangsu JDK Biotechnology Co., Ltd. The company's other major product is freeze-dried purified hamster kidney cell rabies vaccine for human use, which also holds a leading position in China. At present, the company has 3 products under R&D - influenza vaccine for elders, herpes zoster vaccine and 13-valent pneumonia vaccine, which are all in the preclinical phase.
Hemoporfin, the core product of Taizhou Fudan-Zhangjiang Pharmaceutical Co., Ltd., is the world's first drug for nevus flammeus and one of the 2 Category 1.1 new drugs cross China that gained production approval in 2016. "Our company has obtained independent pricing power. The market price of Hemoporfin is RMB 3,980 per vial, and our sales is expected to reach RMB 120 million this year." The company's director said. In addition, the company has a batch of drugs under R&D, and will gradually build a modern drug manufacturing base in CMC that integrates a variety of drug forms and specifications and mainly produces innovative products.
After they are completed and put into operation, these 10 major industrialization projects are expected to contribute an annual sales of RMB 5 billion in 2 to 3 years, injecting new energy to CMC's sustainable development.